Onkozentrum Dresden/Freiberg

Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy (2023) Harbeck N, Kates R, Schinköthe T, Schumacher J, Wuerstlein R, Degenhardt T, Lüftner D, et al. Journal article, Review article Pathologic response after induction chemo-immunotherapy with single or double immune checkpoint inhibition in locally advanced head and neck squamous cell carcinoma (HNSCC): Expansion cohorts of the CheckRad-CD8 trial. (2022) Hecht M, Eckstein M, Kallies A, Klautke G, Illmer T, von der Grün J, Laban S, et al. Conference contribution F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trial (2022) Beck M, Hartwich J, Eckstein M, Schmidt D, Gostian AO, Müller-Hübner S, Rutzner S, et al. Journal article A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer (2021) Hecht M, Hahn D, Wolber P, Hautmann MG, Reichert D, Weniger S, Belka C, et al. Journal article Implementation of double immune checkpoint blockade increases response rate to induction chemotherapy in head and neck cancer (2021) Semrau S, Gostian AO, Traxdorf M, Eckstein M, Rutzner S, von der Grün J, Illmer T, et al. Journal article Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study (2021) Wockel A, Brucker C, Decker T, Falbrede J, Forstbauer H, Gohler T, Hoffmann O, et al. Conference contribution Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8 (2020) Hecht M, Gostian AO, Eckstein M, Rutzner S, Von Der Grün J, Illmer T, Hautmann MG, et al. Journal article Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer (2020) Hecht M, Hahn D, Wolber P, Hautmann MG, Reichert D, Weniger S, Belka C, et al. Journal article Single cycle induction treatment with cisplatin/docetaxel plus durvalumab/tremelimumab in stage III-IVB head and neck squamous cell cancer (CheckRad-CD8 trial) (2019) Hecht M, Gostian AO, Eckstein M, Rutzner S, Von Der Gruen J, Illmer T, Hautmann MG, et al. Conference contribution Advanced renal cell carcinoma: First results from the prospective research platform CARAT for patients with mRCC in Germany (2019) Goebell P, Mueller L, Gruellich C, Reichert D, Boegemann M, Doerfel S, Von Der Heyde E, et al. Conference contribution